Feature

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma

For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv pl...

Share

  • 1

    Teclistamab combined with daratumumab shows 83% risk reduction in progression.

  • 2

    587 patients evaluated with a primary focus on progression-free survival.

  • 3

    Overall survival significantly better with the combination therapy.

  • 4

    Infection rates initially high; guidelines for management have been implemented.

  • 5

    Teclistamab shows promise as the new standard for treatment of relapsed multiple myeloma.

Original Source(s)

MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma

  • by Caroline Helwick

  • March 20, 2026

Related Content

FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma

Nivolumab (Opdivo) with doxorubicin, vinblastine, and dacarbazine (AVD) was approved today for adult and pediatric patients aged 12 years and older with previously untreated stage III or IV classical ...

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission